Cevaretigene Ritoparvovec is a gene therapy commercialized by MeiraGTx, with a leading Phase II program in Leber Congenital Amaurosis (LCA). According to Globaldata, it is involved in 3 clinical trials, of which 2 were completed, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Cevaretigene Ritoparvovec’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Cevaretigene Ritoparvovec is expected to reach an annual total of $33 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Cevaretigene Ritoparvovec Overview
AAV-RPE65 is under development for the treatment of Leber congenital amaurosis type 2 (LCA2). The drug candidate contains adeno-associated virus (AAV)-OPTRPE65. It is administered by intraocular route (subretinal) and acts by targeting retinal pigment epithelium 65 (RPE 65). It is developed based on transformative gene regulation technology platform.
MeiraGTx Overview
MeiraGTx is a clinical-stage genetic medicine company. It develops treatments for ocular, salivary gland and central nervous system diseases. The company’s product pipeline includes AAV-RPGR, AAV-RPE65, AAV-CNGB3, A006, AAV-GAD, AAV-UPF1 and AAV-AQP1. MeiraGTx’ pipeline treats X-linked retinitis pigmentosa, gene deficiency, achromatopsia, macular degeneration, parkinson’s disease, amyotrophic lateral sclerosis, radiation-induced xerostomia and ophthalmology diseases. Its products are used in the medical industry, specifically in the treatment of diseases of the eye, salivary gland, and central nervous system. The company operates in the UK, Ireland, and the US. MeiraGTx is headquartered in New York city, New York, the US.
The company reported revenues of (US Dollars) US$14 million for the fiscal year ended December 2023 (FY2023), a decrease of 12% over FY2022. The operating loss of the company was US$137.1 million in FY2023, compared to an operating loss of US$116.4 million in FY2022. The net loss of the company was US$84 million in FY2023, compared to a net loss of US$129.6 million in FY2022.
The company reported revenues of US$0.3 million for the second quarter ended June 2024, a decrease of 59.5% over the previous quarter.
For a complete picture of Cevaretigene Ritoparvovec’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.